Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Debt (2017 - 2024)

United Therapeutics (UTHR) has disclosed Non-Current Debt for 13 consecutive years, with $100.0 million as the latest value for Q2 2024.

  • Quarterly Non-Current Debt fell 87.5% to $100.0 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $100.0 million through Jun 2024, down 87.5% year-over-year, with the annual reading at $300.0 million for FY2023, 62.5% down from the prior year.
  • Non-Current Debt hit $100.0 million in Q2 2024 for United Therapeutics, down from $200.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $800.0 million in Q1 2020 to a low of $100.0 million in Q2 2024.
  • Historically, Non-Current Debt has averaged $683.3 million across 5 years, with a median of $800.0 million in 2020.
  • Biggest five-year swings in Non-Current Debt: soared 33.33% in 2020 and later tumbled 87.5% in 2024.
  • Year by year, Non-Current Debt stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then tumbled by 62.5% to $300.0 million in 2023, then plummeted by 66.67% to $100.0 million in 2024.
  • Business Quant data shows Non-Current Debt for UTHR at $100.0 million in Q2 2024, $200.0 million in Q1 2024, and $300.0 million in Q4 2023.